TheraRadar
Data updated: May 26, 2026

LEXAPRO (escitalopram oxalate)

Trial Activity: Expansion 3 active trials
CNS Approved 2002-08-14

Lexapro is indicated for the treatment of: • major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older.

Source: FDA Label • FOREST LABS

Development Insights

University of Michigan conducting 1 trials (20%)
7 indications explored (Moderate)
major depressive disorder (2 trials)
irritable bowel syndrome with constipation (1 trials)
alzheimer disease (1 trials)
6
Indications
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2002-08-14
Patent Cliff
2026

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET, SOLUTION

Companies

Active Ingredient: ESCITALOPRAM OXALATE

LEXAPRO Approval History

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
118 FDA actions from 2002 to 2024 · 3 indication expansions
Apr 2024 SUPPL
Label · Labeling
Aug 2023 SUPPL
Label · Labeling
May 2023 SUPPL
Efficacy

What LEXAPRO Treats

6 FDA approvals

Originally approved for its first indication in 2002 . Covers 6 distinct patient populations.

  • Other (6)

LEXAPRO Boxed Warning

SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior s in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . Lexapro is not approved for use in pediatric patients less than 7 years of age [ s ee Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AN D BEHAVIOR...

📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT05004987 21-00535 Ph 4 recruiting Aβ Dynamics in LLMD
NCT05519683 Home-TEA HUM00217301 5UH3NS115108-04 Ph 2, Ph 3 recruiting Home Transcutaneous Electrical Acustimulation (TEA)
NCT05737511 02/2023 Ph 4 not yet recruiting Efficacy of Hydroxyzine for Patients With Panic Disorder
NCT01401595 NES results posted 806753 Ph 3 completed Brain Imaging and Treatment Studies of the Night Eating Syndrome
NCT01894815 ELECT-TDCS ELECT-TDCS FAPESP 2012/20911-5 Ph 3 completed Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEXAPRO FDA Label Details

Indications & Usage

FDA Label (PDF)

Lexapro is indicated for the treatment of: • major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older. Lexapro is a selective serotonin reuptake inhibitor (SSRI) indicated for the: treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior s in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behavio...

LEXAPRO Patents & Exclusivity

Exclusivity: May 2026

Exclusivity

NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
Source: FDA Orange Book

Track LEXAPRO with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment